JPET xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Prasad, D. R.
Right arrow Articles by Steele, T. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Prasad, D. R.
Right arrow Articles by Steele, T. H.

Diuretic-induced uricosuria: interaction with pyrazinoate transport in man

DR Prasad, IM Weiner and TH Steele

We investigated the acute effect of an orally administered uricosuric natriuretic agent (SKF-62698) on renal urate transport in paired clearance studies in seven normal men. The participants received SKF- 62698 on two separate occasions. Prior to the second study, each received pyrazinamide (PZA) in order to inhibit the tubular secretion of urate. Within 3 hours, SKF-62698 significantly decreased the plasma urate and trebled the rate of urate excretion in the studies without PZA. In contrast, after PZA pretreatment. SKF-62698 did not diminish the plasma urate appreciably and elicited only 60% of the previous increase in urate excretion. Sodium excretion quadrupled after SKF- 62698, irrespective of the presence of PZA. Plasma concentrations of pyrazinoate, the renally active metabolite of PZA, were at levels previously shown in the chimpanzee to primarily inhibit the tubular secretion of urate. Therefore, intact tubular secretion of urate probably was necessary in order for SKF-62698 to elicit its maximum uricosuric response. SKF-62698 appeared to inhibit the tubular secretion of pyrazinoate, but the observed changes in urate transport could not be explained on that basis.

Volume 200, Issue 1, pp. 58-64, 01/01/1977
Copyright © 1977 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
 PhysiologyHome page
F. Roch-Ramel and B. Guisan
Renal Transport of Urate in Humans
Physiology, April 1, 1999; 14(2): 80 - 84.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1977 by the American Society for Pharmacology and Experimental Therapeutics.